ASLAN Refills Pipeline With Homegrown Immuno-Onc Asset
Executive Summary
Singapore's ASLAN has signed its second deal in the past few weeks, acquiring global rights to an early stage immuno-oncology molecule that helps to fill a pipeline hole left by a recent out-licensing deal with Bristol-Myers Squibb.
You may also be interested in...
ASLAN Firms Up IPO Plans As Lead Asset Progresses
Amid recent progress for its lead molecule, ASLAN has firmed up plans for the timing of its initial public offering, which is now expected to take place in Taiwan mid May with the newly listed shares set to begin trading in early June.
Deal Watch: Novartis, Cerulean Team To Develop Nanoparticle-Drug Conjugates
Leveraging the brain power behind the first approved IPF drug, Esbriet, small companies Antegrin and Cascadia merge to form the fibrosis-centered Indalo Therapeutics. Gedeon Richter in-licenses a biosimilar of Roche’s Herceptin.
BMS Reacquisition Bulks Up ASLAN’s Deal Chest
Singapore's ASLAN has licensed back to originator BMS the Asian rights to a novel oncology molecule with potential as both a mono and combination therapy, boosting funding for potential future deals in the process.